Older breast cancer patients in England less likely to survive

June 6, 2018, Cancer Research UK

Older women diagnosed with breast cancer in England are less likely to survive their disease than those in Belgium, Poland, Ireland and the Netherlands according to research published today in the British Journal of Cancer.

In one of the largest studies of its kind looking at aged 70 and over, researchers found that England ranked worst out of the selected countries for five year survival for cancer at stage two and three.

The team based at the Leiden University Medical Centre in The Netherlands analysed the anonymised records of 236,015 women who'd been diagnosed with breast cancer before it had spread.

They also found patients with stage one or two breast cancer in England are most likely to have no surgery as part of their treatment compared with other countries.

Not having surgery at stage three was found to be linked to poorer survival. In England 44% of patients received no surgery at stage three, compared to 22% of patients in Belgium.

Overall the number of patients with stage three breast cancer surviving their disease for five years or more in England (48%) was 12% lower than in Belgium (60%).

Author Dr. Marloes Derks said: "The fact in England is higher than in other countries in this study even for those women whose is in its earliest stage suggests there is something more at play than just a failure to diagnose it early.

"We were surprised to see England had lower levels of and further research is needed to establish whether these two factors are linked."

Professor Arnie Purushotham, senior clinical adviser at Cancer Research UK, said: "We know that surgery is one of the most effective treatments for so it's vital that women in England aren't missing out on surgical treatment that could save their lives.

"We need to better understand why patients in England are less likely to have surgery than their European counterparts. Surgery should be considered in all older patients who are fit to undergo this treatment.

"While the thought of an operation might sometimes be daunting, breakthroughs in surgical techniques have meant that for many patients a lumpectomy with minimal surgery to the armpit glands can be just as effective as more radical treatment."

Explore further: Surgery benefits older women with breast cancer

More information: et al, Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group, British Journal of Cancer (2018). DOI: 10.1038/s41416-018-0090-1

Related Stories

Surgery benefits older women with breast cancer

May 23, 2018
In a BJS (British Journal of Surgery) analysis of 18,730 older patients with oestrogen receptor- positive breast cancer in the UK, the risk of dying from breast cancer was greater in patients treated with primary endocrine ...

Disparities found in lung cancer care, survival in US versus England

May 1, 2018
Despite steady declines in death rates in recent years, lung cancer remains the leading cause of cancer deaths in wealthy countries. In a new study, Yale researchers collaborated with investigators in Europe to examine lung ...

Cancer patients diagnosed early are more likely to avoid chemotherapy

October 26, 2017
Cancer patients are around five times more likely to have surgery to remove their tumour, and less likely to have chemotherapy, if they are diagnosed at the earliest stage compared to the latest stage, according to new figures.

Older women may not be offered breast reconstruction after mastectomy

February 8, 2017
A national study from England indicates that older women are often not offered immediate breast reconstruction following a mastectomy, even though guidelines state that surgeons should discuss reconstruction with all suitable ...

Treatment of elderly breast cancer patients varies between different European countries

September 27, 2015
First results from the largest international comparison of the treatment of elderly patients with breast cancer have shown there are substantial differences in the use of surgery, hormone therapy and chemotherapy between ...

Breast cancer drug not recommended for use in England

September 4, 2017
The drug fulvestrant (Faslodex) has not been recommended in England to treat late stage breast cancer, in draft guidance.

Recommended for you

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

Combining three treatment strategies may significantly improve melanoma treatment

December 12, 2018
A study by a team led by a Massachusetts General Hospital (MGH) investigator finds evidence that combining three advanced treatment strategies for malignant melanoma—molecular targeted therapy, immune checkpoint blockade ...

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

New insight into stem cell behaviour highlights therapeutic target for cancer treatment

December 12, 2018
Research led by the University of Plymouth and Technische Universität Dresden has identified a new therapeutic target for cancer treatment and tissue regeneration – a protein called Prominin-1.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.